NWBO
Price
$0.25
Change
-$0.00 (-0.00%)
Updated
Jul 3 closing price
Capitalization
362.31M
XERS
Price
$4.75
Change
+$0.02 (+0.42%)
Updated
Jul 3 closing price
Capitalization
760.74M
30 days until earnings call
Interact to see
Advertisement

NWBO vs XERS

Header iconNWBO vs XERS Comparison
Open Charts NWBO vs XERSBanner chart's image
Northwest Biotherapeutics
Price$0.25
Change-$0.00 (-0.00%)
Volume$1.33M
Capitalization362.31M
Xeris Biopharma Holdings
Price$4.75
Change+$0.02 (+0.42%)
Volume$1.08M
Capitalization760.74M
NWBO vs XERS Comparison Chart in %
Loading...
NWBO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NWBO vs. XERS commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NWBO is a Hold and XERS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (NWBO: $0.25 vs. XERS: $4.73)
Brand notoriety: NWBO and XERS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NWBO: 56% vs. XERS: 0%
Market capitalization -- NWBO: $362.31M vs. XERS: $760.74M
NWBO [@Biotechnology] is valued at $362.31M. XERS’s [@Biotechnology] market capitalization is $760.74M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NWBO’s FA Score shows that 0 FA rating(s) are green whileXERS’s FA Score has 0 green FA rating(s).

  • NWBO’s FA Score: 0 green, 5 red.
  • XERS’s FA Score: 0 green, 5 red.
According to our system of comparison, NWBO is a better buy in the long-term than XERS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NWBO’s TA Score shows that 5 TA indicator(s) are bullish while XERS’s TA Score has 6 bullish TA indicator(s).

  • NWBO’s TA Score: 5 bullish, 6 bearish.
  • XERS’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, XERS is a better buy in the short-term than NWBO.

Price Growth

NWBO (@Biotechnology) experienced а -0.60% price change this week, while XERS (@Biotechnology) price change was -0.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

XERS is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XERS($761M) has a higher market cap than NWBO($362M). XERS YTD gains are higher at: 39.528 vs. NWBO (-9.554). XERS has higher annual earnings (EBITDA): -4.34M vs. NWBO (-74.92M). XERS has more cash in the bank: 58.4M vs. NWBO (2.78M). NWBO has less debt than XERS: NWBO (69M) vs XERS (269M). XERS has higher revenues than NWBO: XERS (223M) vs NWBO (1.47M).
NWBOXERSNWBO / XERS
Capitalization362M761M48%
EBITDA-74.92M-4.34M1,727%
Gain YTD-9.55439.528-24%
P/E RatioN/AN/A-
Revenue1.47M223M1%
Total Cash2.78M58.4M5%
Total Debt69M269M26%
FUNDAMENTALS RATINGS
NWBO vs XERS: Fundamental Ratings
NWBO
XERS
OUTLOOK RATING
1..100
5710
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
91
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6240
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NWBO's Valuation (36) in the Biotechnology industry is somewhat better than the same rating for XERS (91) in the Pharmaceuticals Major industry. This means that NWBO’s stock grew somewhat faster than XERS’s over the last 12 months.

NWBO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as XERS (100) in the Pharmaceuticals Major industry. This means that NWBO’s stock grew similarly to XERS’s over the last 12 months.

NWBO's SMR Rating (100) in the Biotechnology industry is in the same range as XERS (100) in the Pharmaceuticals Major industry. This means that NWBO’s stock grew similarly to XERS’s over the last 12 months.

XERS's Price Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as NWBO (62) in the Biotechnology industry. This means that XERS’s stock grew similarly to NWBO’s over the last 12 months.

XERS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as NWBO (100) in the Biotechnology industry. This means that XERS’s stock grew similarly to NWBO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NWBOXERS
RSI
ODDS (%)
Bullish Trend 5 days ago
89%
N/A
Stochastic
ODDS (%)
Bullish Trend 5 days ago
80%
Bearish Trend 5 days ago
75%
Momentum
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
79%
MACD
ODDS (%)
Bearish Trend 5 days ago
89%
Bullish Trend 5 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 5 days ago
83%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 8 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
90%
Bullish Trend 5 days ago
79%
Aroon
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
NWBO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BSTSX74.160.95
+1.30%
BlackRock Technology Opportunities Svc
ATECX109.380.82
+0.76%
AB Sustainable Global Thematic C
BMIAX7.430.05
+0.68%
BNY Mellon Income Stock A
WAGSX13.290.08
+0.61%
Wasatch Global Select Investor
MXHTX10.15N/A
N/A
Empower International Growth Instl

NWBO and

Correlation & Price change

A.I.dvisor tells us that NWBO and CCCC have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NWBO and CCCC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NWBO
1D Price
Change %
NWBO100%
+0.85%
CCCC - NWBO
24%
Poorly correlated
-2.63%
CBUS - NWBO
23%
Poorly correlated
+2.65%
XERS - NWBO
23%
Poorly correlated
N/A
GLUE - NWBO
22%
Poorly correlated
+2.96%
VRTX - NWBO
21%
Poorly correlated
+0.57%
More

XERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, XERS has been loosely correlated with TRDA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XERS
1D Price
Change %
XERS100%
N/A
TRDA - XERS
53%
Loosely correlated
N/A
AURA - XERS
45%
Loosely correlated
+1.55%
YMAB - XERS
45%
Loosely correlated
+0.94%
XNCR - XERS
45%
Loosely correlated
+1.45%
CGON - XERS
44%
Loosely correlated
+0.82%
More